Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 15 of 65 · 3081 articles
A company claims a novel quantum-based method has highlighted potential drug targets in diseases including Crohn’s disease, which could influence future drug discovery approaches. Investment by CDT Equity signals...
Understanding how individual diet and microbiome patterns relate to disease activity could help create personalized dietary approaches for children with Crohn's disease and improve monitoring using home fecal...
This trial investigates a new oral medication (PALI-2108) for moderate-to-severe ulcerative colitis and could expand treatment options if later trials show benefit and safety. The study focuses on clinical remission at...
Researchers tested whether alpha-lipoic acid — an antioxidant with potential anti-inflammatory effects — can improve symptoms and quality of life when added to standard mesalamine treatment for mild-to-moderate...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from BMC Gastroenterology.
Long-term real-world data on filgotinib help patients and clinicians understand how durable benefits and risks are over 2 years, including likelihood of staying on therapy and changes in inflammation markers.
The review suggests baseline corticosteroid use may change how well some advanced UC therapies work, especially IL-23 inhibitors and S1P modulators, which could affect treatment choices and trial reporting.
Mirikizumab showed higher rates of clinical and endoscopic remission than placebo in pooled randomized trials, which could expand treatment options for people with moderate-to-severe ulcerative colitis if confirmed by...
An animal study found two probiotic strains reduced inflammation and inflammasome markers in an experimental ulcerative colitis model, which could inform veterinary treatments and early-stage research relevant to IBD.
Based on the title and source metadata, this appears to be a clinical trial phase 2 related to Crohn's disease, Stricture, and Research and clinical trials. The original article is from firstwordpharma.com.
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Depression, and Research and clinical trials. The original article is from Cellular and Molecular...
Perianal fistulas in Crohn’s disease are often hard to treat; this review suggests stem cell therapies can produce durable closure for many patients and appear safe over 1–4 years of follow-up.
This study provides real-world data suggesting the oral α4-integrin antagonist carotegrast methyl can improve patient-reported stool frequency and rectal bleeding in many people with ulcerative colitis who did not...
The study suggests that correcting low vitamin D in people with IBD may shift immune responses toward tolerance of gut microbes and associate with lower inflammation—information that could affect monitoring and...
Fatigue greatly affects quality of life for people with IBD even in remission; if effective and scalable, a mobile CBT program could offer accessible symptom support. The trial will also examine engagement factors...
Self-management programs that teach cognitive behavioral strategies, symptom tracking, relaxation, sleep and diet skills could help people with IBD manage symptoms and day-to-day quality of life without relying solely on...
This press release announces upcoming presentations of early clinical and biomarker data for PALI-2108, a gut‑targeted oral PDE4 prodrug being developed for UC and Crohn’s disease. Patients and clinicians may see new...
This preclinical study suggests a heat‑inactivated probiotic strain reduced colitis signs in mice and changed gut microbes and inflammatory pathways—findings that could inform future research into microbiome‑based or...
This preclinical study suggests a specific probiotic strain (Lp05) can increase regulatory T cells and reduce inflammation in a mouse colitis model, which could point to new microbiome-based approaches for IBD in the...
The study suggests a specific macrophage pathway (TRPV1→miR‑31/Wnt16) by which high‑fat diets may worsen intestinal inflammation and fibrosis, offering possible targets for future IBD research relevant to patients with...
Metabolic interactions between epithelial and immune cells may help explain persistent inflammation and barrier problems in IBD and point to new therapeutic targets that could complement current immune-targeting drugs.
The review links changes in the microbiome and microbial polyamine production to immune cell imbalance that can drive both oral inflammation and IBD. Understanding this pathway could point to new research directions and...
ER stress may be a pathway connecting what people eat with intestinal inflammation in IBD. Understanding this could eventually help tailor diets or develop therapies, but human evidence is still limited.
Systemic glucocorticoids used for UC can cause bone loss; identifying early, noninvasive markers could let clinicians detect steroid-induced osteoporosis sooner and intervene to reduce fracture risk.
Microbiome composition differed between relapse and remission in ulcerative colitis in this study; specific bacterial and fungal taxa were statistically associated with clinical and endoscopic activity and are proposed...
The intestinal mucosal barrier is central to ulcerative colitis. If probiotics can strengthen that barrier, they might reduce inflammation or help maintain remission. This review summarizes mechanistic and early clinical...
A PopPK model for subcutaneous infliximab could enable more personalized dosing when starting or switching patients to home-administered infliximab, potentially improving drug exposure and management for people with IBD.
This study suggests that even when people with IBD are in clinical and biological remission on long-term biologic therapy, their gut microbiome composition and inferred functions can still differ from laboratory...
AI-assisted detection tools and disease-specific optical classifications could improve lesion detection and real-time characterization during UC surveillance, potentially affecting surveillance accuracy and...
Colon-targeted prednisolone devices could lower upper-GI exposure to steroids and provide sustained local therapy, which may be relevant for IBD treatment strategies if later validated in vivo and in clinical trials.
Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...
The case links thymic hyperplasia, thyroid autoimmunity, and severe UC with colorectal neoplasia, suggesting possible shared immune dysregulation that might interest patients and clinicians, but it does not support...
If you or your clinician are choosing between advanced therapies for ulcerative colitis, this study suggests past vedolizumab use may be linked to lower likelihood of responding to ustekinumab.
If validated, prealbumin — a routine blood protein test reflecting nutrition and inflammation — could help predict who with Crohn’s disease is more likely to need abdominal surgery or to have endoscopic recurrence after...
m6A RNA methylation is a regulator of RNA function that may influence inflammation, immunity, and the intestinal microbiota — all central to IBD. Understanding these pathways could identify new biomarkers or drug targets...
Patients with IBD who may need dupilumab for another immune condition could benefit from evidence about whether combining dupilumab with IBD biologics or advanced therapies changes infection or healthcare-utilization...
Finding genetic variants that correlate with country-level IBD burden could help researchers study why IBD rates differ geographically and point to biological pathways relevant to disease risk and outcomes.
This study describes a novel, non‑drug HA‑based nano‑assembly that targets inflammatory M1 macrophages and reshapes the colonic immune environment in mouse models of ulcerative colitis — a potential new therapeutic...
New Phase II trials test whether a gut-activated oral PDE4 inhibitor can treat moderate-to-severe ulcerative colitis and Crohn’s while avoiding systemic PDE4 tolerability issues; positive Phase II results could add a new...
This project seeks new biology-based treatments for IBD by finding bacterial enzymes that block PAR signaling, a pathway linked to inflammation, barrier loss, and pain — symptoms many people with Crohn’s disease or...
This project targets epithelial repair — a mechanism not directly addressed by most current IBD drugs — and reports early human safety/tolerability data, so it could lead to a new oral therapy for inducing and...
Researchers are studying how gut bacteria evade therapeutic phages, which could affect development of phage-based treatments for drug-resistant infections and potentially influence understanding of bacteria linked to IBD...
Malnutrition and impaired growth are common at diagnosis in paediatric IBD—especially Crohn’s disease—and identifying these issues early can guide nutrition and treatment planning. Most underweight children in this study...
This study maps a shared transcriptional programme linking inflamed IBD tissue to colorectal cancer pathways, highlighting potential biomarker and prevention targets relevant to the inflammation-to-cancer transition.
Fecal calprotectin is commonly used to monitor IBD activity. If bowel prep raises calprotectin modestly, that could affect how post-procedure results are interpreted and avoid unnecessary treatment changes.
Tools that predict which microbial or tumor peptides engage patient T cells could help researchers find antigens that trigger or drive autoimmune conditions (like some IBD cases) or that serve as targets for...
This study describes an engineered probiotic that senses a validated IBD inflammation biomarker (calprotectin) and produces IL‑2 locally, offering a potential new way to deliver anti‑inflammatory therapy on demand.
Antibiotics can substantially change gut microbes; for people with IBD those changes may affect inflammation and gut barrier function. The review summarizes microbiome-targeted strategies that patients and clinicians may...
